Get emergency medical help if you have any of these signs of an allergic reaction to Netlook: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using Netlook and call your doctor at once if you have any of these serious side effects:
depressed mood, trouble concentrating, sleep problems, crying spells, aggression or agitation, changes in behavior, hallucinations, thoughts of suicide or hurting yourself;
sudden numbness or weakness, especially on one side of the body;
blurred vision, sudden and severe headache or pain behind your eyes, sometimes with vomiting;
hearing problems, hearing loss, or ringing in your ears;
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
severe diarrhea, rectal bleeding, black, bloody, or tarry stools;
fever, chills, body aches, flu symptoms, purple spots under your skin, easy bruising or bleeding;
severe blistering, peeling, and red skin rash; or
joint stiffness, bone pain or fracture.
Less serious Netlook side effects may include:
joint pain, back pain;
feeling dizzy, drowsy, or nervous;
dryness of the lips, mouth, nose, or skin; or
cracking or peeling skin, itching, rash, changes in your fingernails or toenails.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Side effects of Netlook in details
A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.
The following adverse reactions with Netlook or other Netlook products are described in more detail in other sections of the labeling:
Serious Skin Reactions
Inflammatory Bowel Disease
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Netlook cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.
The adverse reactions listed below reflect both clinical experience with Netlook, and consider other adverse reactions that are known from clinical trials and the post-marketing surveillance with oral Netlook. The relationship of some of these events to Netlook therapy is unknown. Many of the side effects and adverse events seen in patients receiving Netlook are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage, and eyes).
Cheilitis and hypertriglyceridemia are adverse reactions that are usually dose related. Most adverse reactions reported in clinical trials with Netlook were reversible when therapy was discontinued; however, some persisted after cessation of therapy.
Body as a Whole
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): fatigue, irritability, pain. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: allergic reactions, including vasculitis, systemic hypersensitivity, edema, lymphadenopathy, weight loss.
The following adverse reactions have been reported with Netlook: vascular thrombotic disease, stroke, palpitation, tachycardia.
Endocrine/Metabolism and Nutritional
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): decreased appetite, weight fluctuation, hyperlipidaemia. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: hypertriglyceridemia, alterations in blood sugar.
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): lip dry, chapped lips, cheilitis, nausea, constipation, diarrhea, abdominal pain, vomiting. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: inflammatory bowel disease, hepatitis, pancreatitis, bleeding and inflammation of the gums, colitis, esophagitis/esophageal ulceration, ileitis, and other nonspecific gastrointestinal symptoms.
The following adverse reactions have been reported with Netlook: allergic reactions, anemia, thrombocytopenia, neutropenia, rare reports of agranulocytosis.
Infections and infestations
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): nasopharyngitis, hordeolum, upper respiratory tract infection. In addition to the above adverse reactions, the following adverse reaction has been reported with Netlook: infections (including disseminated herpes simplex).
The following changes in laboratory tests have been noted in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): blood creatine phosphokinase (CPK) increased, blood triglycerides increased, alanine aminotransferase (SGPT) increased, aspartate aminotransferase (SGOT) increased, gamma-glutamyltransferase (GGTP) increased, blood cholesterol increased, low density lipoprotein (LDL) increased, white blood cell count decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood glucose increased, high density lipopoprotein (HDL) decreased, bone mineral density decreased. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: increased LDH, elevation of fasting blood sugar, hyperuricemia, decreases in red blood cell parameters, decreases in white blood cell counts (including severe neutropenia and rare reports of agranulocytosis), elevated sedimentation rates, elevated platelet counts, thrombocytopenia, white cells in the urine, proteinuria, microscopic or gross hematuria.
Musculoskeletal and Connective Tissue
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): decreases in bone mineral density, musculoskeletal symptoms (sometimes severe) including back pain, athralgia, musculoskeletal discomfort, musculoskeletal pain, neck pain, pain in extremity, myalgia, musculoskeletal stiffness. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: skeletal hyperostosis, calcification of tendons and ligaments, premature epiphyseal closure, tendonitis, arthritis, transient pain in the chest, and rare reports of rhabdomyolysis.
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): headache, syncope. In addition to the above adverse reactions, other adverse reactions reported with Netlook include: pseudotumor cerebri, dizziness, drowsiness, lethargy, malaise, nervousness, paresthesias, seizures, stroke, weakness.
The following adverse reactions have been reported in clinical trials conducted with Netlook and a generic product of Netlook® (Netlook): suicidal ideation, insomnia, anxiety, depression, irritability, panic attack, anger, euphoria, violent behaviors, emotional instability. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: suicide attempts, suicide, aggression, psychosis and hallucination auditory. Of the patients reporting depression, some reported that the depression subsided with discontinuation of therapy and recurred with reinstitution of therapy.
The following adverse reaction has been reported with Netlook: abnormal menses.
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): epistaxis, nasal dryness. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: bronchospasms (with or without a history of asthma), respiratory infection, voice alteration.
Skin and Subcutaneous Tissue
The following adverse reactions have been reported in a clinical trial conducted with Netlook and a generic product of Netlook® (Netlook): dry skin, dermatitis, eczema, rash, dermatitis contact, alopecia, pruritus, sunburn, erythema. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: acne fulminans, alopecia (which in some cases persists), bruising, dry nose, eruptive xanthomas, erythema multiforme, flushing, fragility of skin, hair abnormalities, hirsutism, hyperpigmentation and hypopigmentation, nail dystrophy, paronychia, peeling of palms and soles, photoallergic/photosensitizing reactions, pruritus, pyogenic granuloma, rash (including facial erythema, seborrhea, and eczema), Stevens-Johnson syndrome, sunburn susceptibility increased, sweating, toxic epidermal necrolysis, urticaria, vasculitis (including Wegener's granulomatosis), abnormal wound healing (delayed healing or exuberant granulation tissue with crusting).
Hearing: The following adverse reactions have been reported with Netlook: tinnitus and hearing impairment.
Ocular: The following adverse reactions have been reported in clinical trials conducted with Netlook and a generic product of Netlook® (Netlook): dry eye, visual acuity reduced, vision blurred, eye pruritis, eye irritation, asthenopia, decreased night vision, ocular hyperemia, increased lacrimation, and conjunctivitis. In addition to the above adverse reactions, the following adverse reactions have been reported with Netlook: corneal opacities, decreased night vision which may persist, cataracts, color vision disorder, conjunctivitis, eyelid inflammation, keratitis, optic neuritis, photobia, visual disturbances.
Renal and Urinary
The following adverse reactions have been reported in clinical trials conducted with Netlook: glomerulonephritis, nonspecific urogenital findings.
What is the most important information I should know about Netlook?
Netlook may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Netlook with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
Do NOT take more than the recommended dose or take Netlook for longer than prescribed without checking with your doctor. Doing so will not improve your condition faster and may increase your risk for side effects.
A sudden decrease in night vision may occur while you are taking Netlook. Use caution when driving at night and avoid driving at night if you experience decreased night vision.
If you wear contact lenses, you may have difficulty wearing them during and after therapy.
Do not donate blood while taking Netlook and for 1 month after you stop taking Netlook.
Do not drink alcohol while taking Netlook.
Worsening of acne may occur during the first part of therapy. This does not suggest failure or a need to stop the medicine.
To prevent cracking of lips, use a lip moisturizer or balm.
Do not have cosmetic procedures to smooth your skin, including waxing, dermabrasion, or laser procedures, while you are taking Netlook and for at least 6 months after you stop taking it. Netlook can increase your chance of scarring from these procedures.
Netlook may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Netlook. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.
Some patients have become depressed or developed serious mental or mood problems while taking Netlook. Stop using Netlook and tell your health care provider right away if you have any new, worsened, or sudden symptoms, such as feeling sad or having crying spells; feeling anxious; becoming more irritable, angry, or aggressive than usual; losing pleasure or interest in social or sports activities; sleeping too much or too little; changes in weight or appetite; feeling like you have no energy; having trouble concentrating; or having thoughts about taking your life or hurting yourself (suicidal thoughts).
Netlook may cause decreased bone strength in some patients. Patients who play vigorous impact sports may be at increased risk of bone problems (eg, fractures). Discuss any questions or concerns with your doctor.
Women who may become pregnant must use 2 effective forms of birth control at least 1 month before starting therapy, during therapy, and for 1 month after stopping the medicine. Your health care provider should conduct pregnancy tests on a monthly basis while you are taking Netlook.
Do not use progestin-only pills or "minipills" (pills that do not contain estrogen) for birth control because they may not work as well with Netlook. Ask your doctor or pharmacist if you are not sure what type of birth control pills you are using.
Women who use hormonal birth control should avoid the use of the herbal supplement St. John's wort because it may decrease the effectiveness of hormonal birth control.
Diabetes patients - Netlook may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.
Lab tests, including pregnancy tests, cholesterol and lipid levels, liver function, blood sugar levels, and white blood cell counts, may be performed while you use Netlook. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
Netlook may affect normal growth in some CHILDREN. Caution is advised when using Netlook in children; they may be more sensitive to its effects. Consult your doctor for more details.
Netlook should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.
PREGNANCY and BREAST-FEEDING: Do not use Netlook if you are pregnant. It has been shown to cause serious birth defects, miscarriage, early birth, or death of the fetus. Avoid becoming pregnant while you are taking it. If you have sex at any time without using 2 forms of effective birth control, become pregnant, think you may be pregnant, or miss your menstrual period, stop using Netlook and call your doctor right away. It is not known if Netlook is found in breast milk. Do not breast-feed while taking Netlook and for 1 month after stopping Netlook.
Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.
Hypersensitivity to Netlook or to any of the excipients of Netlook. Hepatic or renal insufficiency; hypervitaminosis A; patients with excessively elevated blood lipid values.
Use in pregnancy: Pregnancy Category X: Netlook is highly teratogenic. It is, therefore, contraindicated not only in women who are pregnant or who may become pregnant while undergoing treatment but also in all women of childbearing potential. There is an extremely high risk that a deformed infant will result if pregnancy occurs while taking Netlook in any amount even for short periods. Potentially all exposed foetuses can be affected.
Netlook is contraindicated in women of childbearing potential unless the female patient meets all of the following conditions: Severe disfiguring cystic acne resistant to standard therapies; reliability in understanding and carrying out instructions; compliance with the mandatory contraceptive measures; informed by the physician of the hazards of becoming pregnant during and 1 month after treatment with Netlook and warned of the possibility of contraceptive failure; confirms that patient has understood the warnings; negative pregnancy test within 2 weeks prior to beginning therapy, monthly repetition of pregnancy testing is recommended; use effective contraception without any interruption for at least 1 month before beginning Netlook therapy, during therapy and for 1 month following discontinuation of therapy. At least 1 and preferably 2 complementary forms of contraception including a barrier method should be used. Microdosed progesterone preparations (minipills) may be an inadequate method of contraception during Netlook therapy. If the patient starts Netlook therapy only on the 2nd or 3rd day of the next menstrual period; in the event of relapse treatments, patient must also use the same uninterrupted and effective contraceptive measures 1 month prior to, during and for 1 month after Netlook therapy; must fully understand the precautions and confirm patient understanding and willingness to comply with reliable contraceptive measures as explained.
Even female patients, who normally do not employ contraception because of a history of infertility, should be advised to do so while taking Netlook, following the previously stated guidelines.
Should pregnancy occur inspite of these precautions during treatment with Netlook or in the month following, there is a great risk of very severe malformation of the foetus (involving in particular the central nervous system, heart and large blood vessels). If pregnancy does occur, the physician and patient should discuss the advisability of continuing the pregnancy.
Major human foetal abnormalities related to Netlook administration have been documented, including hydrocephalus, microcephalus, abnormalities of the external ear (micropinna, small or absent external auditory canals), microphthalmia, cardiovascular abnormalities, facial dysmorphia, thymus gland abnormalities, parathyroid hormone deficiency and cerebellar malformation. There is also an increased risk of spontaneous abortion.
Netlook is highly teratogenic and must not be given to women who are pregnant. Netlook crosses the placental barrier in amounts that lead to congenital deformities. There is an extremely high risk that a deformed infant will result if pregnancy occurs while taking Netlook in any amount even for short periods. Potentially all exposed foetuses can be affected.
DailyMed. "ISOTRETINOIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
DTP/NCI. "Isotretinoin: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
European Chemicals Agency - ECHA. "Isotretinoin: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Netlook are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Netlook. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
2 consumers reported side effects
Did you experience side effects while taking Netlook drug? According to the report by ndrugs.com, the below mentioned statistics discuss the number of people who experienced side effects after taking Netlook drug. Every drug produces at least minor unwanted effects, which we call side effects. The side effects can be bothersome, or they can be minor so patients do not know they are experiencing them. The side effects of the drug depend on the individual, severity of disease, symptom, and associated conditions in the patient. The most deciding factor is the drug dosage. The higher the dosage, the higher the therapeutic result, and the more side effects. Every patient need not have the same intensity of side effect. When the side effects are greater, immediately consult your health care provider.
It has side effects
There are no reviews yet. Be the first to write one!